Essa Pharma Inc (ESSQF) 11.2221 $ESSQF
ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market
PR Newswire - Thu Jul 02, 5:16PM CDT
ESSA Pharma Inc. ("ESSA" or the "Company"

(TSX-V: EPI) announced today that its common shares have been approved for listing and trading on the NASDAQ Capital Market ("NASDAQ"

under the symbol "EPIX".
EPI.VN: 10.910 (-0.590)
ESSA Pharma Inc. Announces Appointment of New Director
PR Newswire - Wed Jun 24, 3:20PM CDT
ESSA Pharma Inc. ("ESSA" or the "Company"

(TSX-V: EPI) announced today that it has appointed Dr. David Parkinson to its board of directors. Dr. Parkinson's appointment as an independent director is effective immediately.
EPI.VN: 10.910 (-0.590)
Essa Pharma Inc. Reports Second Quarter 2015 Financial Results
CNW Group - Thu May 28, 5:19PM CDT
ESSA Pharma Inc. ("ESSA" or the "Company"

(TSX-V: EPI) today reported financial results for the second quarter and three and six months ended March 31, 2015. Amounts, unless specified otherwise, are expressed in Canadian dollars and in accordance with International Financial Reporting Standards ("IFRS"

.
EPI.VN: 10.910 (-0.590)
ESSA Pharma Inc. Receives FDA Response on IND Application
CNW Group - Mon May 04, 6:00AM CDT
ESSA Pharma Inc. ("ESSA" or the "Company"

(TSX-V: EPI) announced today that it has received notification from the Food and Drug Administration ("FDA" or the "Agency"

in the US that the Company's IND application, filed March 31, 2015, has been placed on clinical hold pending receipt by the FDA of additional chemistry and pharmaceutical data related to the stability of the drug substance and drug product and a Certificate of Analysis on drug product.
EPI.VN: 10.910 (-0.590)
ESSA Pharma Inc. Announces Filing of Investigational New Drug Application for EPI-506
CNW Group - Tue Mar 31, 2:01PM CDT
ESSA Pharma Inc. ("ESSA" or the "Company"

(TSX-V: EPI) announced today that it has filed with the Food and Drug Administration ("FDA"

in the US an Investigation New Drug ("IND"

application related to the Company's proposed clinical trial of EPI-506 in prostate cancer patients. Approval of the IND application is required in order for ESSA to commence human testing of EPI-506 in the US.
EPI.VN: 10.910 (-0.590)